Specialty & Blends
Tirzepatide (30 mg) + BPC-157 (30 mg)
Made in the USAA two-component research blend of Tirzepatide and BPC-157. Tirzepatide is studied for combined GIP and GLP-1 receptor signaling in metabolic regulation, while BPC-157 research explores tissue responses, fibroblast activity and repair-related pathways. This presentation combines constituents with these complementary research interests.
What is it researched for?
Primary research focus: Specialty & Blends. This description is not a medical indication.
Presentations & pricing
30mg/30mg · $865
Request this product
Select a presentation above to update the vial, label and inquiry. The team confirms availability and next steps.
Research information only; this page does not provide dosing, prescribing or treatment instructions. Verify regulatory status and documentation for the applicable product and lot.